The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...
Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...
CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results